Nuveen’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Nuveen’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-224,252	Closed	-$10.4M	–	3268
2023 Q2	$10.4M	Buy	224,252 +92,823	+71%	+$3.21M	﹤0.01%	1489
2023 Q1	$3.77M	Sell	131,429 -12,310	-9%	-$365K	﹤0.01%	2045
2022 Q4	$4.48M	Buy	143,739 +55,240	+62%	+$1.8M	﹤0.01%	1975
2022 Q3	$1.79M	Sell	88,499 -1,604	-2%	-$29.2K	﹤0.01%	2451
2022 Q2	$1.4M	Buy	90,103 +58,059	+181%	+$999K	﹤0.01%	2623
2022 Q1	$613K	Buy	32,044 +10,980	+52%	+$196K	﹤0.01%	2956
2021 Q4	$533K	Buy	+21,064	New	+$617K	﹤0.01%	3061

Nuveen's DICE Position: Q3 2023 in Review

Nuveen sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 224,252 shares — an estimated $10.4M sold.

Nuveen first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $10.4M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Nuveen reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Nuveen sold 224,252 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $10.4M.
Nuveen first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Nuveen's DICE Therapeutics, Inc. Common Stock position peaked at $10.4M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Nuveen's 13F filing for Q3 2023, filed 14 Nov 2023.